¼¼ºê¶õ½ºº´¿ø 2019 ´ëÇÑÇ÷¾×ÇÐȸ CML/MPN ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2019-05-18±³À°ÀÏÀÚ : 2019-05-18
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø ABMRC 1Ãþ À¯ÀÏÇÑȦ
±³À°ÁÖÁ¦ :
2019 ´ëÇÑÇ÷¾×ÇÐȸ CML/MPN ¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 09:00~09:30 Significance of mutation study in MPN diagnosis, treatment, and prognosis ±è´ë½Ä(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 09:30~10:00 Approach and treatment of blastic phase of MPNs À±ÀçÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 10:00~10:30 Mastocytosis ÃÖÀºÁö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 10:40~11:00 New studies of MPN 2019 (I) À̼¼·Ã(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 11:00~11:20 New studies of MPN 2019 (II) ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 11:20~11:40 New studies of MPN 2019 (III) ±è¼º¿ë(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 13:00~13:25 The argument for using imatinib in CML ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 13:25~13:50 Molecular monitoring in CML: how deep? How often? How should it influence therapy? ÀåÁöÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 13:50~14:15 We do still transplant CML, don¡¯t we? ±èÇõ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 14:30~15:10 Cutting edge of molecular target therapy and therapeutic strategy in CML Yoske Minami(National Cancer Center Hospital East, Japan)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 15:10~15:35 Advances in genomics and laboratory techniques in CML/MPN À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 15:35~16:00 CML in adolescence Çѽ¹Î(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 16:15~16:40 Updates of CML 2019 - Biology and Pathophysiology ÀÌÇý¿ø(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-18 À¯ÀÏÇÑȦ 16:40~17:05 Updates of CML 2019 – therapy ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)